Skip to main content
Premium Trial:

Request an Annual Quote

Pharma Spending Growth Rate May Never Reach 'Boom' of '00-'01, Bruker CEO Says

NEW YORK (GenomeWeb News) – The rate of growth at which drug makers invest in life science tools and technologies may never reach the levels seen during the 2000 or 2001 “boom,” according to Bruker BioSciences CEO Frank Laukien.
 
“It’s certainly better than it has been [recently] but may never again be at the 2000-2001 levels,” Laukien said during a break-out session following his presentation at the UBS Life Sciences Conference here today.
 
Laukien said pharma spending “continues to be pretty selective and judicious” across all life science tool segments. “I don’t think it’s realistic to expect [the spending growth] to return to the boom levels of 2000,” he said.
 
Laukien’s comments were an expansion of a pronouncement he made last month when he said that "pharma [spending] in the first half of the year … has been healthier than a year ago. Clearly, pharma and biotech are still restrained in their spending, but it is healthier in general." These remarks were originally reported in GenomeWeb News publication BioCommerce Week
 
During his UBS presentation he said that pharma spending “for all of our businesses has gone up in the last few quarters.”
 
As GenomeWeb News publication ProteoMonitor reported in July, Bruker’s proteomics rivals Thermo Electron and Waters said that while pharma spending continued to slow in the second quarter, their proteomics businesses remained a bright spot.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.